GIBaren kontrako tratamendua. Berrikuspen historikoa.

  1. Víctor Torre
  2. Begoña Ugarte Uribe
  3. Maier Lorizate Nogales
  4. L. Ruth Montes
Journal:
Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria

ISSN: 0214-9001

Year of publication: 2020

Issue: 38

Pages: 97-116

Type: Article

DOI: 10.1387/EKAIA.20855 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria

Abstract

Despite its relatively recent emergence, HIV has managed to become a public health problem on a global scale and according to the WHO[1] it standed in the top 10 causes of death until 2016. When it first appeared the reaction of health systems in developed countries was slow, but HIV soon became one of the most studied viruses. Nowadays we know many of the details of its biology, its life cycle and the pathophysiology of the disease it causes: the Acquired Immunodeficiency Syndrome (AIDS). This knowledge promted the pharmacological research, which, from a few compounds of limited efficacy, managed to create several families of molecules. Although these molecules are not capable to eradicate the virus, they have turned a deadly infection into a chronic disease, specially in the first world countries, where the provision of these drugs is guaranteed. The development of new drugs against HIV was arduous and it became possible thanks to the advances in molecular biology, physics and pharmaceutical chemistry that took place in the last century. However, there is still a long way to go and, although there are still many aspects of HIV to be elucidated, some deep changes in its treatment can be foreseen in the upcoming years.